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Abstract: BACKGROUND Inflammatory bowel disease (IBD) is a chronic inflammatory disorder, pri-
marily of, but not restricted to, the gut. Association between IBD and cancer has been clearly established
and is uniformly accepted. SUMMARY IBD patients are at particular risk for intestinal and extrain-
testinal cancers. There are 2 underlying mechanisms: (1) IBD-related inflammation triggers initiation
and progression of tumor formation. This particularly results in the development of colorectal cancer,
small bowel adenocarcinoma, intestinal lymphoma, anal cancer, and cholangiocarcinoma. (2) Immuno-
suppressive drugs exhibit carcinogenic properties such as shown for azathioprine and anti-TNF promoting
lymphoproliferative malignancies and melanoma and nonmelanoma skin cancer. However, within the last
years, IBD-related cancer incidence and prevalence have been decreasing, which might be attributed to
better treatment options and surveillance strategies. Moreover, novel biological drugs have been intro-
duced in clinical practice and have dramatically changed long-term IBD management. Therefore, we
sought to summarize up-to-date knowledge about (1) overall cancer risk; (2) risk and protective fac-
tors for cancer development; and (3) inflammation- and immunosuppression-related malignancies in the
current anti-TNF era of IBD. Key Messages: Recent studies and meta-analyses questioned the excess
rates of cancer in IBD patients. However, IBD still is associated with cancer development due to on-
going intestinal inflammation and the use of potential carcinogenic drugs. Patients should be educated
about the increased risk of cancer with IBD and IBD drugs. However, they should also be informed that
most malignancy subtypes are possibly preventable by controlling intestinal inflammation and by using
adequate screening strategies.
DOI: https://doi.org/10.1159/000509544






The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Greuter, Thomas; Vavricka, Stephan; König, Alexander O; Beaugerie, Laurent; Scharl, Michael (2020).




Malignancies in Inflammatory Bowel 
Disease
Thomas Greuter a, e    Stephan Vavricka a, b    Alexander O. König c    
Laurent Beaugerie d    Michael Scharl a    on behalf of Swiss IBDnet, an official 
working group of the Swiss Society of Gastroenterology 
aDepartment of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland; bCenter for 
Gastroenterology and Hepatology, Zurich, Switzerland; cDepartment of Gastroenterology and Hepatology, University 
of Göttingen, Göttingen, Germany; dDepartment of Gastroenterology, Sorbonne Université, INSERM, Institut Pierre 
Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Paris, France; eDepartment of Internal 
Medicine, GZO - Zurich Regional Health Center, Wetzikon, Switzerland
Received: June 28, 2019
Accepted: May 11, 2020
Published online: August 14, 2020
Thomas Greuter
Department of Gastroenterology and Hepatology
University Hospital Zürich, Rämistrasse 100
CH–8091 Zurich (Switzerland) 
thomas.greuter @ usz.ch
© 2020 The Author(s)





Inflammatory bowel disease · Malignancy · Cancer ·  
Anti-TNF · Immunosuppression
Abstract
Background: Inflammatory bowel disease (IBD) is a chronic 
inflammatory disorder, primarily of, but not restricted to, the 
gut. Association between IBD and cancer has been clearly 
established and is uniformly accepted. Summary: IBD pa-
tients are at particular risk for intestinal and extraintestinal 
cancers. There are 2 underlying mechanisms: (1) IBD-related 
inflammation triggers initiation and progression of tumor 
formation. This particularly results in the development of 
colorectal cancer, small bowel adenocarcinoma, intestinal 
lymphoma, anal cancer, and cholangiocarcinoma. (2) Immu-
nosuppressive drugs exhibit carcinogenic properties such as 
shown for azathioprine and anti-TNF promoting lymphopro-
liferative malignancies and melanoma and nonmelanoma 
skin cancer. However, within the last years, IBD-related can-
cer incidence and prevalence have been decreasing, which 
might be attributed to better treatment options and surveil-
lance strategies. Moreover, novel biological drugs have been 
introduced in clinical practice and have dramatically changed 
long-term IBD management. Therefore, we sought to sum-
marize up-to-date knowledge about (1) overall cancer risk; 
(2) risk and protective factors for cancer development; and 
(3) inflammation- and immunosuppression-related malig-
nancies in the current anti-TNF era of IBD. Key Messages: 
Recent studies and meta-analyses questioned the excess 
rates of cancer in IBD patients. However, IBD still is associ-
ated with cancer development due to ongoing intestinal in-
flammation and the use of potential carcinogenic drugs. Pa-
tients should be educated about the increased risk of cancer 
with IBD and IBD drugs. However, they should also be in-
formed that most malignancy subtypes are possibly pre-
ventable by controlling intestinal inflammation and by using 
adequate screening strategies. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Inflammatory bowel disease (IBD) with its 2 subtypes, 
Crohn’s disease (CD) and ulcerative colitis (UC), is char-
acterized by a chronic inflammation of the intestine [1]. 
However, it has been known for years that inflammatory 
activity in IBD is not restricted to the gut, but can occur 
at various extraintestinal sites [2]. IBD is a common dis-
order in the Western Hemisphere with an estimated 
This is an Open Access article licensed under the Creative Commons 
Attribution-NonCommercial-4.0 International License (CC BY-NC) 
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prevalence of 246.7/100,000 for CD and 286.3/100,000 for 
UC [3]. Cancer represents the second leading cause of 
death worldwide (after cardiovascular diseases); it is esti-
mated that one out of 2 individuals will suffer from ma-
lignancy during life [4]. Given the frequency of these 2 
diseases, co-occurrence does not necessarily imply asso-
ciation or causality. However, the concept of inflamma-
tion resulting in cancer development is clearly estab-
lished. The German pathologist Rudolf Virchow first sug-
gested a causal relation between inflammatory processes 
and tumor formation based on his observations of leuko-
cytes within cancer tissue [5]. This was back in 1863 [6]. 
One hundred fifty years later, numerous inflammatory 
processes have been linked to cancer development such 
as viral hepatitis (to hepatocellular carcinoma), Helico-
bacter pylori gastritis (to gastric cancer), pancreatitis (to 
pancreatic adenocarcinoma), or mononucleosis (to lym-
phoma). In IBD, inflammation has been linked to colorec-
tal cancer development; studies have shown a 2-fold in-
crease in the risk for colorectal carcinoma, particularly in 
patients with extensive colonic inflammation and longer 
disease duration [7]. Ongoing colonic inflammatory in-
sults result in initiation and progression of cancer forma-
tion through step-wise mechanisms [8].
Increased cancer risk in IBD goes beyond intestinal 
malignancies. Extraintestinal cancer appears to occur 
more frequently than it would be expected from the gen-
eral population [7, 9, 10]. Examples here are cholangio-
carcinoma, lymphoma, and melanoma and nonmelano-
ma skin cancer. Case-control and large nation-wide co-
hort studies have revealed that some of these malignancies 
are triggered by immunosuppressive treatment such as 
thiopurines or anti-TNF rather than by intestinal inflam-
mation [11–16]. Based on these observations, IBD-relat-
ed malignancies are currently classified into 2 groups: (1) 
cancers resulting from IBD activity (inflammation-relat-
ed) and (2) cancers related to IBD treatment (immuno-
suppression-related; Fig. 1) [7]. Some cancer types such as 
EBV-related primary intestinal lymphoma in patients ex-
posed to thiopurines are attributed to both inflammation 
and IBD treatment. Besides immunosuppressive drugs’ 
carcinogenic potential, their chemopreventive properties 
should also be kept in mind, such as described for 5-ASA 
[17–19].
Within the last years, IBD-related cancer incidence 
and prevalence have been decreasing, which might be at-
tributed to better treatment options and surveillance 
strategies [7, 9, 20]. In addition, new biological drugs have 
been introduced in clinical practice and have dramati-
cally changed long-term IBD management. Therefore, we 
sought to summarize up-to-date knowledge about (1) 
overall cancer risk; (2) risk and protective factors for can-
cer development; and (3) inflammation- and immuno-
suppression-related malignancies in the current anti-
TNF era of IBD. This review will not discuss the available 
treatment options for specific cancer subtypes.
Epidemiology
Malignancy Overall
Several studies from nation-wide cohorts revealed ex-
cess risk of cancer in IBD patients, more so in CD than 
















Fig. 1. Classification of cancer in IBD patients into the 2 categories of inflammation-related and immunosup-
pression-related malignancies. IBD, inflammatory bowel disease.
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Fig. 2. Forest plots for development of can-
cer overall, colon cancer, lymphoma, and 
melanoma based on the major available co-
hort studies. All data are stratified by IBD 
subtype (CD vs. UC). The results are shown 
from the cohort studies of Bernstein et al. 
(Canada) [70], Kappelman et al. (Den-
mark) [10], Jess et al. (Denmark) [9], So et 
al. (China) [71], Jussila et al. (Finland) [72], 
Hovde et al. (Norway) [73], and Pederson 
et al. (meta-analysis of European studies) 
[74]. IBD, inflammatory bowel disease; 
BCC, basal cell carcinoma; NA, not appli-
cable; CD, Crohn’s disease; UC, ulcerative 
colitis.
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adenocarcinoma, colorectal carcinoma, and anal carci-
noma), biliary tract cancer, and hematological malignan-
cies (myeloma and non-Hodgkin lymphoma). However, 
a thorough review conducted by European experts re-
cently considered the overall risk of IBD-related cancer to 
be of limited magnitude [21]. Indeed, a pan-European 
study revealed – while acknowledging excess risk for cer-
tain cancer types – no increased rates of overall cancer in 
IBD patients [22]. Consistently, a meticulous analysis of 
the Swiss IBD cohort demonstrated cancer rates that were 
comparable to the general population based on a follow-
up of 12,420.8 patient years [23]. Taken together, the risk 
of IBD-related cancer overall and specific subtypes ap-
pears to be increased, although to a lesser extent than re-
ported in the past. For standardized incidence ratios (SIR) 
for development of cancer overall, colon cancer, lympho-
ma, and melanoma (and their respective confidence in-
tervals) reported in the major available cohort studies, see 
Figure 2. An SIR of 1.0 indicates a rate that is identical to 
that expected from the general population.
Risk Factors for Cancer Development
Numerous risk factors for the development of intesti-
nal and extraintestinal cancer (including medications) 
have been identified, although specific pharmaceutical 
compounds may exhibit both harmful and chemopreven-
tive properties. Two of the best established specific risk 
factors are (1) extent of colonic disease and (2) disease 
duration [7]. The more the colonic area is affected and the 
longer the IBD has been active, the higher the risk for 
colorectal cancer. These findings have laid the ground for 
recommendations in terms of screening intervals in IBD 
patients (see the section Colorectal Cancer). In contrast, 
patients with isolated rectal disease do not appear to have 
an increased risk for colorectal cancer [24]. Another well-
studied risk factor is the presence of primary sclerosing 
cholangitis (PSC) [7]. PSC has been shown to increase the 
risk for both colorectal cancer and cholangiocarcinoma 
[7, 20, 25, 26]. Patients with PSC should therefore under-
go annual screening colonoscopies regardless of IBD ac-
tivity. In addition, abdominal ultrasonography and/or 
MRI should be performed every year. Thiopurines have 
long been known to have a carcinogenic effect. Several 
cancer types have been associated with the use of azathio-
prine and 6-mercaptopurine. Among those are lympho-
ma, urinary tract cancer, and nonmelanoma skin cancer 
[7, 11–14, 27, 28]. Of note, azathioprine has been associ-
ated with excess risk for the development of cancer over-
all [23]. Best evidence evolves from the French CESAME 
study. The use of thiopurines was associated with an in-
creased risk of lymphoproliferative disorders; in CD, 
lymphoma rates were increased, while in both UC and 
CD, risk for leukemia was higher than what would have 
been expected from the general population [11]. Of note, 
the carcinogenic effect of thiopurines appears to be re-
versible upon the drug’s withdrawal. Despite immuno-
suppressive drugs’ potentially deleterious effects, they can 
also lower cancer risk through controlling inflammation. 
So, one might assume a vulnerable equilibrium, where 
either too much inflammation or too much immunosup-
pression can be harmful. Controlling inflammation could 
be more important as in 1 study anti-TNF use was associ-
ated with an overall decreased risk of cancer development 
[23]. The involvement of TNF and its role in carcinogen-
esis is however very complex. While the aforementioned 
factors are rather specific to IBD, several non-IBD-related 
factors have been linked to cancer development such as 
increased age, smoking, and positive family history for 
cancer.
Protective Factors
Few protective factors have been identified. As previ-
ously mentioned, anti-TNF use has been associated with 
a lower incidence of cancer overall, which might be at-
tributed to a better control of intestinal inflammation 
[23]. Nonetheless, this finding has to be interpreted cau-
tiously as it is based on a retrospective analysis and could 
be biased by the fact that patients with high cancer risk 
are less likely treated with anti-TNF. Data on 5-ASA che-
mopreventive properties have been conflicting. Few stud-
ies have shown decreased rates of colorectal cancer in 
both UC and CD [17–19], while no such effect was seen 
in a nonreferral IBD population [29].
Inflammation-Related Malignancies
Ongoing intestinal inflammation has been associated 
with the following cancer types: colorectal carcinoma, 
small bowel adenocarcinoma, intestinal lymphoma, anal 
carcinoma, and cholangiocarcinoma (Fig. 1) [7]. These 
cancers are potentially preventable with the use of immu-
nosuppressive and biologic agents.
Colorectal Cancer
Colorectal cancer represents the third most common 
cancer type worldwide [30]. Incidence rates are estimat-
ed at 45.8/100,000 for males and 29.2/100,000 for females 
(National Institute for Cancer Epidemiology and Regis-
tration in Switzerland NICER). Survival rates have been 
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reported to range from 14 to 90% depending on disease 
stage with an overall 5-year survival rate of 64% (SEER 
database of the National Cancer Institute, SEER = Sur-
veillance, Epidemiology, and End Results). Because 
colorectal cancer is so frequent, it might occur in IBD 
patients just by chance. However, besides these sporadic 
cases, an association of colorectal cancer with inflamma-
tion (so-called colitis-associated cancer) has been clearly 
established. IBD patients are at increased risk for colorec-
tal cancer except subjects without colonic inflammation. 
Particular risk factors are extensive colonic disease, long 
disease duration, severity of colonic disease, and pres-
ence of PSC [7]. While patients with ulcerative proctitis 
are not at increased risk [24], UC patients with left-sided 
colitis have an intermediate and those with pancolitis 
have a maximal risk for the development of colorectal 
cancer [31]. For CD, a colonic involvement of at least 
30–50% is considered to result in an excess risk [7, 32]. 
Frequency of early cancer is low and patients do not seem 
to be at increased risk during the first 7 years [31]. How-
ever, after 6–8 years, the risk for colorectal cancer is high-
er than that seen in the general population and increases 
annually in a linear fashion [7, 33]. Based on these find-
ings, the European Crohn’s and Colitis Organization 
(ECCO) developed the following guidelines [31]: after 
6–8 years, colonoscopy should be performed (i) annu-
ally in case of PSC, colorectal cancer in a first-degree rel-
ative younger than 50 years, strictures within the past 5 
years, or dysplasia within past 5 years in a patient declin-
ing surgery; (ii) every 3 years in case of postinflamma-
tory polyps, colorectal cancer in a first-degree relative 
older than 50 years, and extensive colitis with moderate 
to severe activity; and (iii) every 5 years if colitis affects 
<50% of the colon or if there is extensive colitis with mild 
activity. Besides IBD-specific risk factors, the following 
traditional risk factors for colorectal cancer have to be 
taken into account: male sex, family history, age, smok-
ing, low physical activity, and consumption of red meat 
and alcohol [7]. Despite the well-accepted concept of 
colitis-induced carcinogenesis, the increased risk of 
colorectal cancer in IBD has been questioned lately. No 
excess risk was found in a Danish study and a recent me-
ta-analysis [20, 33]. There are several explanations for 
these findings: (1) the introduction of novel and potent 
immunosuppressive drugs has led to better control of in-
testinal inflammation; (2) screening strategies have im-
proved; (3) colectomy has been implemented in more 
countries for high-grade dysplasia; and (4) certain drugs 
may have chemopreventive properties [23]. However, 
despite these promising data, it can still be assumed – al-
though to a lesser extent than previously thought – that 
IBD results in a 2-fold increase in the risk of colorectal 
cancer [34].
Pathogenesis of IBD-related colon cancer appears to 
be similar to that of sporadic cases. Inflammation and 
consecutive inflammatory insults result in the initiation 
and progression of carcinogenesis [8]. In a first step, 
changes occur on a molecular level such as TP53 muta-
tions, microsatellite instability, or CpG island methyla-
tion [35, 36]. This then leads to histological dysplasia 
ranging from indefinite to low and finally high-grade 
dysplastic lesions [37, 38]. Loss of APC, a known tumor 
suppressor gene mutated in patients with familial adeno-
matous polyposis (FAP), usually occurs at a late stage [7]. 
Changes in the microbiota have recently been recognized 
as a potential contributor to tumor formation. Despite 
similar pathogenesis, IBD-associated dysplastic lesions 
are flatter and have less distinct borders compared with 
sporadic precancerous lesions and are therefore less 
amenable to early detection and preventive removal dur-
ing screening colonoscopies [7]. This should be kept in 
mind when dealing with IBD patients. Dysplastic lesions 
might be missed with standard endoscopy techniques. 
Therefore, ECCO recommends either high-definition/
chromoendoscopy with targeted biopsies or standard en-
doscopy with random biopsies (at least 33) [31]. Colec-
tomy should follow if high-grade dysplasia or carcinoma 
is detected, which is not amenable to endoscopic resec-
tion.
Based on the current knowledge, the following ap-
proaches are recommended to prevent development of 
colorectal cancer: (1) colonic disease and inflammation 
should be controlled as much as possible and (2) screen-
ing for colorectal cancer should start 6–8 years after IBD 
diagnosis or earlier in case of additional risk factors. It 
remains to be proven whether or not 5-ASA and thiopu-
rines indeed have chemopreventive properties. The ben-
efit from aspirin in IBD patients is unknown and – as of 
yet – cannot be recommended. Still, IBD patients al-
ready taking aspirin for other reasons should keep doing 
so.
Small Bowel Adenocarcinoma
Adenocarcinoma of the small bowel is a rare disease 
with a cumulative incidence rate of 30 per 100,000 patient 
years [39]. However, these rates are considerably higher 
in IBD patients. Small bowel CD, particularly if long 
standing, results in an excess risk for small bowel cancer, 
that is, 20–30 times higher than that seen in the general 
population [40]. Rates appear to be lower in the anti-TNF 
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era [23]. In contrast to the colon, the small bowel is not 
easily amenable to preventive strategies, and optimal 
screening strategies have yet to be defined. Broad imple-
mentation of capsule endoscopy is limited by the risk of 
capsule retention in case of stenotic disease.
Intestinal Lymphoma
Lymphomas in the intestine are generally rare, but 
might occur with a frequency of up to 10–48.3 per 100,000 
patient years in IBD [23, 41]. Indeed, there appears to be 
a 3-fold increase in IBD patients compared with the gen-
eral population [23]. IBD-related lymphomas are typical-
ly of the B-cell non-Hodgkin subtype and are found in 
chronically inflamed intestinal lesions [7, 41]. Particular 
risk factors for development of intestinal lymphoma are 
(1) extensive inflammation, (2) middle-aged males, and 
(3) long disease duration (>8 years) [41]. Since EBV is of-
ten detected in intestinal lymphoma cells and association 
between EBV and lymphoma has been shown for other 
lymphoma subtypes, inflammation-promoted EBV rep-
lication is thought to be a main contributor to this type of 
malignancy [42].
Anal Carcinoma
Gastroenterologists may be reluctant to screen for anal 
cancers. A proper rectal examination is essential for the 
identification of this tumor. Although incidence is low 
(0.01–0.02/1,000), several risk factors have been identi-
fied: males who have sex with males, females with high-
grade cervical dysplasia, and presence of fistula in pa-
tients with long-standing perianal CD [7, 43]. In the lat-
ter, the incidence increases to 0.38 per 1,000 patient years 
[44]. While anal cancers are usually of squamous epithe-
lial origin and related to HPV infection, cancers arising 
from fistula can be either adenocarcinoma or squamous 
cell carcinoma [7]. These cancers are not associated with 
HPV infection. Prognosis of anal carcinoma is generally 
poor.
Cholangiocarcinoma
Rates for cholangiocarcinoma appear to be 2–6-fold 
higher in IBD patients compared with the general popu-
lation [7, 25, 26]. Reported crude incidence might be as 
high as 24.2/100,000 [23]. Cholangiocarcinoma is al-
most uniformly detected in IBD patients with PSC [26]. 
Here, the risk for cholangiocarcinoma is increased by 
160-fold [45]. PSC patients have a life-time risk for chol-
angiocarcinoma of 5–10% [45]. PSC patients should 
therefore undergo screening for cholangiocarcinoma, 
most probably with either annual abdominal MRCP or 
sonography combined with measuring CA 19–9 serum 
levels. Most importantly, every PSC patient requires 
colonoscopy to check for underlying IBD. Coexistence 
of PSC and IBD is a particular risk factor for the devel-
opment of colorectal cancer and should urge doctors to 
perform screening colonoscopies on annual basis [20, 
31].
Immunosuppression-Related Malignancies
Both conventional immunosuppressive agents and bi-
ologics have been linked to various cancer subtypes, par-
ticularly hematological malignancies and skin cancer 
(both melanoma and nonmelanoma skin cancers; Fig. 1). 
Several pathomechanisms have been suggested. Immu-
nosuppressive agents may cause tumor formation by al-
tering DNA, impairing immune control of chronic infec-
tion by mutagenic viruses such as EBV or HPV, and re-
ducing immunosurveillance of cancer or dysplastic cells 
[7, 46–48].
Hematological Malignancies
Although IBD does not appear to increase the rates of 
lymphoma per se (except for the subtype of intestinal 
lymphoma) [11, 49], NHL have been a particular concern 
in IBD patients. The use of thiopurines is associated with 
the development of EBV-associated B-cell lymphoma 
[11]. Young men seem to be at particular risk (incidence 
of 3 per 1,000 patient years) [11]. Thiopurines have been 
associated with a 5- to 6-fold increased risk for lymphoma 
development [11, 50]. In rare cases, a non-EBV-related 
hepatosplenic T-cell lymphoma has been described with-
in 2 years after treatment initiation in young men [51]. 
Therefore, azathioprine and 6-mercaptopurine should be 
used with caution in this subpopulation and alternative 
agents should be considered such as methotrexate if com-
bination therapy is needed. Thiopurines have further 
been associated with the development of acute myeloid 
leukemia and severe myelodysplastic syndrome [52]. For 
anti-TNF, data are conflicting. Based on the current lit-
erature, it is currently not clear if lymphoma risk is indeed 
elevated in anti-TNF-treated IBD patients [15, 23], but 
long-term dose accumulation could potentially increase 
this risk. Increased rates of lymphoma have been reported 
in rheumatologic studies.
Skin Cancer
Skin cancer is a frequent problem even in young pa-
tients; therefore, occurrence of dermatologic malignan-
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cies in the IBD population is not surprising. Both thiopu-
rines and anti-TNF have been linked to the development 
of skin cancers. Azathioprine and 6-mercaptopurine have 
been associated with an increased risk of nonmelanoma 
skin cancer [13, 14], while no such risk has been seen for 
anti-TNF. However, the latter has been associated with 
development of melanoma [15, 16]. Studies reported a 
1.5–4-fold increased risk [15, 16, 23]. There appears to be 
an intrinsic risk for melanoma in IBD that cannot be ex-
plained by the use of immunosuppressive agents. Based 
on these findings, IBD patients should be regularly seen 
by a dermatologist for evaluation of possible early skin 
cancer lesions [34]. This is particularly recommended for 
patients with light skin types and for those on thiopurines 
and/or anti-TNF treatment.
Cervical Cancer
In few studies, increased rates of cervical cancer have 
been reported in women with IBD. Cervical cancer is typ-
ically associated with HPV infection. As of yet, it remains 
unclear if this is due to an intrinsic risk or due to immu-
nosuppression [53]. In general, the rates of cervical can-
cer have been decreasing over the last decades due to wide 
implementation of screening strategies. In addition, HPV 
vaccination has been widely introduced into clinical prac-
tice. In Switzerland, this vaccination is strongly recom-
mended for all women aged 11–14. Women up to the age 
of 26 are encouraged to get vaccinated. Costs are fully 
covered as part of the cantonal vaccination programs. 
Women with IBD falling into this age category should be 
particularly encouraged to undergo vaccination given the 
clear and well-accepted association between HPV infec-
tion and development of cervical cancer. They should fur-
ther see their gynecologist every 1–2 years. HPV-related 
infections are less frequently observed in men than wom-
en. Still, HPV vaccination should be recommended for 
male subjects.
Urinary Tract Cancer
Use of thiopurines has been associated with increased 
rates of kidney and bladder cancer in transplant recipi-
ents [54]. Similar findings have been shown in the IBD 
population, although the risk is almost completely re-
stricted to older males, particularly smokers [27, 55]. No 
such increase was seen with the use of anti-TNF [15]. In 
patients with a previous history of urogenital cancer and 
the need for immunosuppressive therapy, use of thiopu-
rines should be avoided. The role of screening strategies 
in patients on thiopurine treatment (such as urine cytol-
ogy and/or cystoscopy) remains to be determined.
Future Perspectives
The introduction of anti-TNF into clinical practice 
has dramatically changed IBD management. Newer 
non-anti-TNF biologics further will. Clinicians dealing 
with IBD now have a wide armamentarium of options 
for the treatment of CD and UC: anti-integrins, anti-
IL-12/23, and the newest kid on the block, JAK-inhibi-
tors. Data on their safety profile with regard to cancer 
development are currently emerging. Analysis of the 
GEMINI long-term safety data and postmarketing set-
ting did not show any association of the anti-integrin 
vedolizumab with increased malignancy incidence 
(5,670 patient years) [56]. The JAK-inhibitor tofacitinib 
has not been associated with increased risk for nonmel-
anoma skin cancer and other malignancies based on a 
meta-analysis including 82 studies (66,159 patients) 
[57]. Lastly, the anti-IL-12/23 antibody ustekinumab 
does not appear to increase the risk of cancer develop-
ment (nonmelanoma skin cancers and other malignan-
cies) [58, 59]. Analyses of clinical extensions in psoriasis 
and psoriatic arthritis with a follow-up of 5 and 2 years, 
respectively, are reassuring. However, given a consider-
ably higher number of cancer cases in UC patients treat-
ed with ustekinumab compared with placebo, the asso-
ciation between anti-IL-12/23 and malignancy in IBD 
warrants further investigation [60]. In particular, longer 
follow-up studies are needed (for all non-anti-TNF bio-
logics) in order to assess possible dose accumulation ef-
fect over time.
Tumor screening strategies are important and effec-
tive tools for the prevention and early detection of can-
cer in the general population and IBD patients. How-
ever, data for their efficacy evolve from case series and 
retrospective case-control studies (demonstrating re-
duced rates of colorectal cancer and improved survival) 
[61–67]. Randomized-controlled trials showing a clear 
benefit from colonoscopy in IBD are still lacking [31]. 
Chromoendoscopy with targeted biopsies has been 
demonstrated to increase dysplasia detection rate [68]. 
The role of newer tools such as narrow-band imaging 
and endomicroscopy remains unclear. Trials are re-
quired to define their place in the screening algorithm. 
Further studies are needed with regard to screening 
strategies for cholangiocarcinoma, small bowel adeno-
carcinoma, and urinary tract cancer. From a personal-
ized medicine perspective, it will be interesting to see 
which IBD phenotypes are at particular risk for specific 
cancer subtypes. This will help to individually tailor 
screening recommendations as well as therapeutic strat-
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egies in the future. As of yet, the following recommenda-
tions can be made: thiopurines should be avoided in pa-
tients with a prior history of lymphoma, acute myeloid 
leukemia, myelodysplastic syndrome, nonmelanoma 
skin cancer, and urinary tract cancer, while anti-TNF 
should not be used in patients with a history of mela-
noma [34, 69]. In addition, ECCO guidelines recom-
mend to limit the use of thiopurines in EBV seronega-
tive young men.
Conclusions
Although recent studies and meta-analyses ques-
tioned the excess rates of cancer in IBD patients, IBD still 
is associated with cancer development due to ongoing 
intestinal inflammation and the use of potential carcino-
genic drugs. The latter has been particularly shown for 
thiopurines and anti-TNF. However, more recent data 
from the Swiss IBD cohort revealed that the overall risk 
for cancer might be even lowered with the use of anti-
TNF indicating that there could be a net benefit from 
these agents [23]. This might be attributed to their poten-
tial of deeply controlling intestinal disease activity. Pa-
tients should be educated about the increased risk of can-
cer with IBD and IBD drugs. However, they should also 
be informed that most malignancy subtypes are possibly 
preventable by controlling intestinal inflammation and 
by using adequate screening strategies. Data on the use 
of chemopreventive agents (5-ASA, azathioprine, and 
aspirin) for the pure purpose of cancer prevention is too 
conflicting to give any recommendations. However, 
these drugs should be used for IBD treatment (5-ASA 
and azathioprine) or continued if used for other indica-
tions (aspirin).
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